Literature DB >> 10072408

Rising incidence of hepatocellular carcinoma in the United States.

H B El-Serag1, A C Mason.   

Abstract

BACKGROUND AND METHODS: Clinical observations have suggested that the number of cases of hepatocellular carcinoma has increased in the United States. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) data base to determine the age-adjusted incidence of hepatocellular carcinoma from 1976 to 1995, data from the U.S. vital-statistics data base to determine age-adjusted mortality rates from 1981 to 1995, and data from the Department of Veterans Affairs to determine age-adjusted rates of hospitalization for the disease from 1983 to 1997.
RESULTS: The incidence of histologically proved hepatocellular carcinoma increased from 1.4 per 100,000 population (95 percent confidence interval, 1.3 to 1.4) for the period from 1976 to 1980 to 2.4 per 100,000 (95 percent confidence interval, 2.3 to 2.4) for the period from 1991 to 1995. Among black men, the incidence was 6.1 per 100,000 for the period from 1991 to 1995, and among white men, it was 2.8 per 100,000. There was a 41 percent increase in the mortality rate from primary liver cancer and a 46 percent increase in the proportion of hospitalizations attributable to this disease during the periods studied. The incidence increased significantly among younger persons (40 to 60 years old) during the period from 1991 to 1995 as compared with earlier periods.
CONCLUSIONS: An increase in the number of cases of hepatocellular carcinoma has occurred in the United States over the past two decades. The age-specific incidence of this cancer has progressively shifted toward younger people.

Entities:  

Mesh:

Year:  1999        PMID: 10072408     DOI: 10.1056/NEJM199903113401001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  726 in total

Review 1.  Cirrhosis of liver.

Authors:  B S Anand
Journal:  West J Med       Date:  1999-08

2.  Increased mortality from liver cancer in England and Wales is not related to hepatitis C.

Authors:  S D Taylor-Robinson; H C Thomas; S Arora; S Hargreaves
Journal:  BMJ       Date:  1999-09-04

3.  The science, economics, and effectiveness of combination therapy for hepatitis C.

Authors:  G Dusheiko; E Barnes; G Webster; S Whalley
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

4.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

Review 5.  Current perspectives in cancer proteomics.

Authors:  Miriam V Dwek; Sarah L Rawlings
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

6.  Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure.

Authors:  Yu-Jing Zhang; Hui-Chen Wu; Hulya Yazici; Ming-Whei Yu; Po-Huang Lee; Regina M Santella
Journal:  World J Hepatol       Date:  2012-05-27

7.  Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

Authors:  S D Taylor-Robinson; M B Toledano; S Arora; T J Keegan; S Hargreaves; A Beck; S A Khan; P Elliott; H C Thomas
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

8.  Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.

Authors:  N Obeng-Adjei; D K Choo; J Saini; J Yan; P Pankhong; A Parikh; J S Chu; D B Weiner
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

9.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

10.  Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases.

Authors:  Y-X Chen; Z-C Zeng; J Fan; Z-Y Tang; J Zhou; M-S Zeng; J-Y Zhang; J Sun
Journal:  Clin Transl Oncol       Date:  2013-02-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.